|This message contains images. If you don't see images, click here to view.|
here to advertise in this news brief.
Apply now for the AST 2015 Transplant Nursing Grant
The AST is currently accepting applications for a two-year transplant nursing grant in the amount of $10,000. This grant, being funded by the Wood-MacMillan Foundation, will be awarded for studies that focus on topics related to transplant candidate and recipient outcomes and well-being, quality of life, compliance, and aspects of transplant-related drugs that affect patient care (including dosing, side effects, pharmacokinetics, and pharmacogenetics).
For additional details or to get started on your application, click here. The deadline to submit an application for funding is Monday, Sept. 15, 2015. Additionally, AST is also accepting applications for junior faculty or fellowship grants in basic, clinical, and translational science. Visit the grants page on the AST website for more details.
Now Accepting Abstracts for CEOT 2015
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies
Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona
Share your research with experts in transplantation. Submit your basic, clinical or translational abstract now! Make plans to attend this high-energy, intimate meeting where expert clinicians, leading diagnosticians, and world class scientists will address the field’s cutting edge challenges together with an engaged audience. This year’s CEOT will feature sessions on:
Click here to submit your basic, clinical or translational abstract.
- A Critical Review of Cell Therapies
- Whatever Happened to Gene Therapy?
- Organ Repair and Regeneration, and Organ Generation
- Drug Development and Rediscovering Pathways
OPTN/UNOS educational offerings this fall
Be prepared for changes in the pancreas allocation system, better understand performance monitoring efforts, and gain a comprehensive understanding of UNOS/OPTN processes, policies and methodologies with these three upcoming events:
- Sept. 23: Webinar on Bayesian methods for assessing transplant program performance - Read more
- Oct. 6: Webinar on preparing for the new pancreas allocation system - Read more
- Oct. 27-28: UNOS Primer: Building on Basics - Read more
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
ASN Kidney Week early program on transplantation
Registration Rates Increase Sept. 23, 2014
In recent years, there have been important advances in the field of kidney transplantation that will impact the care of the kidney transplant recipient. ASN, in cooperation with AST, has developed an early program preceding Kidney Week that provides an interactive, case-based overview of exciting advances in kidney transplantation, with a focus upon specific populations, complications, and ethical issues. Nephrologists with an interest in transplantation, transplant physicians, and trainees in the nephrology are encouraged to attend this program. Get full program details and register here.
UPCOMING EVENTS IN TRANSPLANTATION
Discounted registration ends soon
ESOT + AST Joint Meeting
Personalized Transplantation: From New Diagnostics to New Therapeutics
Oct. 17-19, 2014
Register by Sept. 7 to take advantage of early registration and a discounted rate. Join the ESOT and AST in beautiful Madrid, Spain as together we explore:
Click here to learn more about this enlightening meeting, or view the full program.
- New Options to Improve Immunosuppressive Therapy
Belatacept, Anti CD40 trial (ASKP1240), Anti- IL-6 and Tacrolimus formulations
- Novel Diagnostics
Donor DNA - Biomarker of Graft Injury, In vivo Live Imaging of the Immune Response and Tolerance Profile
- Novel Targets for Immunosuppression
B-cells, Plasma Cells and Complement
- Personalized Medicine: Technique and Technology
Sequencing for TCR Repertoire, Pharmacogenetics, Epigenetics and Mixed Chimerism
- Cellular Strategies to Optimize Long Term Outcomes
T-regs, Mesenchymal Cells, Facilitator Cells
The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
Effect of HCV, HIV and coinfection in kidney transplant recipients: Mate kidney analyses
American Journal of Transplantation
Reports of kidney transplantation (KTX) in recipients with hepatitis C virus (HCV+), human immunodeficiency virus (HIV+) or coinfection often do not provide adequate adjustment for donor risk factors. We evaluated paired deceased-donor kidneys (derived from the same donor transplanted to different recipients) in which one kidney was transplanted into a patient with viral infection (HCV+, n = 1700; HIV+, n = 243) and the other transplanted into a recipient without infection (HCV− n = 1700; HIV− n = 243) using Scientific Registry of Transplant Recipients data between 2000 and 2013.
Immunosuppressive effects of erythropoietin on human alloreactive T cells
Journal of the American Society of Nephrology
Correction of anemia with erythropoietin (EPO) is associated with improved kidney transplant outcomes. Emerging evidence, predominantly from animal models, indicates that these observations may be erythropoiesis-independent and that EPO exhibits immunosuppressive properties. This study examined the effects of EPO on human T-cell alloimmunity by first documenting that CD4+ and CD8+ T cells express EPO receptor (EPO-R) on their surfaces.
Patient- and provider-reported information about transplantation and subsequent waitlisting
Journal of the American Society of Nephrology
Because informed consent requires discussion of alternative treatments, proper consent for dialysis should incorporate discussion about other renal replacement options including kidney transplantation (KT). Accordingly, dialysis providers are required to indicate KT provision of information (KTPI) on CMS Form-2728; however, provider-reported KTPI does not necessarily imply adequate provision of information. Furthermore, the effect of KTPI on pursuit of KT remains unclear.
Hydrogen preconditioning during ex vivo lung perfusion improves the quality of lung grafts in rats
Although the benefits of ex vivo lung perfusion (EVLP) have been globally advocated, the potentially deleterious effects of applying EVLP, in particular activation of proinflammatory cascades and alteration of metabolic profiles, are rarely discussed. This study examined proinflammatory events and metabolic profiles in lung grafts on EVLP and tested whether preconditioning lung grafts with inhaled hydrogen, a potent, cytoprotective gaseous signaling molecule, would alter the lungs’ response to EVLP.
Ambulatory ECMO as a bridge to lung transplant in a previously well pediatric patient with ARDS
Extracorporeal membrane oxygenation (ECMO) is increasingly implemented in patients with end-stage pulmonary disease as a bridge to lung transplant. Several centers have instituted an approach that involves physical rehabilitation and ambulation for patients supported with ECMO. Recent reports describe the successful use of ambulatory ECMO in patients with chronic respiratory illnesses being bridged to lung transplant.
Missed last week's issue? See which articles your colleagues read most.
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063